HHS Nominee Eyes New Tacks On Drug Prices, Provider Pay

Law360, New York (January 9, 2018, 6:17 PM EST) -- The Trump administration’s nominee to lead the U.S. Department of Health and Human Services opened the door Tuesday to new approaches for easing drug prices and basing Medicare reimbursement on the performance of health care providers.

Alex Azar, the administration’s pick for HHS secretary, expressed that openness during a confirmation hearing at the Senate Finance Committee. He did so after naming drug prices and quality-based reimbursement as two of his top four priorities, along with the opioid crisis and looser regulation of health insurance policies.

Alex Azar testifies during a Senate Finance Committee hearing on Capitol Hill in Washington on Tuesday...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS